<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Finasteride</id>
	<title>Finasteride - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Finasteride"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Finasteride&amp;action=history"/>
	<updated>2026-05-08T23:01:20Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Finasteride&amp;diff=4960316&amp;oldid=prev</id>
		<title>Prab at 04:15, 8 April 2023</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Finasteride&amp;diff=4960316&amp;oldid=prev"/>
		<updated>2023-04-08T04:15:17Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Finasteride (fih-NAS-teh-ride) is a drug used to reduce the amount of male hormone (testosterone) produced by the body.&lt;br /&gt;
[[File:Finasteride.svg|Finasteride|thumb]]&lt;br /&gt;
{{intro}}&lt;br /&gt;
Finasteride is a 5-alpha reductase inhibitor used to treat symptoms of [[benign prostatic hypertrophy]] and male pattern [[baldness]].&lt;br /&gt;
{{livtox}}&lt;br /&gt;
Finasteride is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of clinically apparent, acute liver injury.&lt;br /&gt;
{{moa}}&lt;br /&gt;
Finasteride (fin as&amp;#039; ter ide) was the first 5-alpha reductase inhibitor to be approved for use as therapy of symptomatic [[benign prostatic hypertrophy]] in the United States. Finasteride inhibits the steroid 5-alpha reductase, which blocks the conversion of testosterone to dihydrotestosterone, a form of the androgenic hormone that is important in the development and maintenance of prostatic hyperplasia. Serum dihydrotesterone levels are decreased by 70% to 90% by finasteride therapy with little effect on testosterone levels. Finasteride takes several months to have an effect on prostate size and symptoms of prostatic hypertrophy ([[urinary hesitancy]] and poor stream), unlike the alpha-1 adrenergic receptor blockers which have a more immediate effect. Finasteride also inhibits the steroid 5-alpha reductase present in skin, which led to its use in the therapy or prevention of male pattern [[baldness]].&lt;br /&gt;
{{fda}}&lt;br /&gt;
Finasteride was approved for use in the United States in 1992 and is available in 5 mg tablets generically and under the trade name Proscar for prostatic hypertrophy, and as 1 mg tablets under the name Propecia for male pattern [[baldness]].&lt;br /&gt;
{{dose}}&lt;br /&gt;
The recommended dose for therapy of prostatic hypertrophy is 5 mg once daily, and it generally requires 3 to 6 months before an effect is obtained and thereafter requires long term therapy. The dose of finasteride for male pattern [[baldness]] is 1 mg daily. It is not recommended as therapy for [[baldness]] in women.&lt;br /&gt;
{{se}}&lt;br /&gt;
Side effects are uncommon, but include a low rate of impotence and decreased [[libido]], [[gynecomastia]], [[dizziness]] and [[weakness]]. Finasteride also decreases serum [[PSA]] levels (~50%), which should be monitored during therapy.&lt;br /&gt;
{{bph drugs}} &lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{Androgens and antiandrogens}}&lt;br /&gt;
{{Drugs used in benign prostatic hypertrophy}}&lt;br /&gt;
{{Other dermatological preparations}}&lt;br /&gt;
{{Merck&amp;amp;Co}}&lt;br /&gt;
{{Portal bar | Medicine}}&lt;br /&gt;
[[Category:5α-Reductase inhibitors]]&lt;br /&gt;
[[Category:Androstanes]]&lt;br /&gt;
[[Category:Merck &amp;amp; Co. brands]]&lt;br /&gt;
[[Category:Carboxamides]]&lt;br /&gt;
[[Category:Hair loss medications]]&lt;br /&gt;
[[Category:Hair removal]]&lt;br /&gt;
[[Category:Delta-lactams]]&lt;br /&gt;
[[Category:Teratogens]]&lt;br /&gt;
[[Category:Tert-butyl compounds]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>